The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Galapagos disavows any obligation to update the information contained in such press releases after the date of their issuance.

English | Dutch
07 January

Positive topline results with GLPG1972 in osteoarthritis patients

02 January

Update on progress in cystic fibrosis programs

07 January

Positive topline results with GLPG1972 in osteoarthritis patients

02 January

Update on progress in cystic fibrosis programs

No content available.

18 December

Transparency notification

14 December

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

11 December

Transparency notification

11 December

Galapagos to enter NASDAQ Biotech Index

23 November

Galapagos increases share capital through warrant exercises

21 November

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

19 November

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

05 November

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

02 November

Galapagos moving forward in CF programs at NACFC 2017

26 October

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

27 September

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

21 September

Galapagos increases share capital through warrant exercises

09 August

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

27 July

Solid financials support R&D progress

27 July

Servier licenses GLPG1972 in osteoarthritis from Galapagos

05 July

New Phase 2 study with filgotinib in non-infectious uveitis

20 June

Galapagos increases share capital through warrant exercises

20 June

Galapagos' R&D Update 2017: rapidly advancing our product candidates

17 May

Galapagos creates new warrant plan

17 May

Galapagos to hold Annual R&D Update 2017 on 20 June

15 May

Seven abstracts on filgotinib accepted by EULAR 2017

07 May

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

29 April

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

27 April

Galapagos reports first quarter 2017 results

25 April

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

21 April

Galapagos announces capital increase

21 April

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

18 April

Galapagos raises $338 million gross proceeds in a U.S. public offering

17 April

Galapagos announces launch of proposed public offering

06 April

Galapagos increases share capital through warrant exercises

05 April

Galapagos doses first psoriatic arthritis patient with filgotinib

04 April

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

23 March

Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings

22 March

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

10 March

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

23 February

Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451

23 February

Galapagos reports strong financial results and newsflow-rich pipeline

01 February

Galapagos doses first patient with novel CF corrector GLPG2222

20 January

Galapagos creates new warrant plan

17 January

Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer

14 December

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

11 December

Galapagos to enter NASDAQ Biotech Index

21 November

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

19 November

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

05 November

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

02 November

Galapagos moving forward in CF programs at NACFC 2017

27 September

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

05 July

New Phase 2 study with filgotinib in non-infectious uveitis

17 May

Galapagos to hold Annual R&D Update 2017 on 20 June

15 May

Seven abstracts on filgotinib accepted by EULAR 2017

07 May

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

29 April

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

25 April

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

06 April

Galapagos increases share capital through warrant exercises

05 April

Galapagos doses first psoriatic arthritis patient with filgotinib

04 April

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

10 March

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

23 February

Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451

17 January

Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer

18 December

Transparency notification

11 December

Transparency notification

23 November

Galapagos increases share capital through warrant exercises

26 October

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

21 September

Galapagos increases share capital through warrant exercises

09 August

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

27 July

Solid financials support R&D progress

27 July

Servier licenses GLPG1972 in osteoarthritis from Galapagos

20 June

Galapagos increases share capital through warrant exercises

20 June

Galapagos' R&D Update 2017: rapidly advancing our product candidates

17 May

Galapagos creates new warrant plan

27 April

Galapagos reports first quarter 2017 results

21 April

Galapagos announces capital increase

21 April

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

18 April

Galapagos raises $338 million gross proceeds in a U.S. public offering

17 April

Galapagos announces launch of proposed public offering

23 March

Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings

22 March

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

23 February

Galapagos reports strong financial results and newsflow-rich pipeline

01 February

Galapagos doses first patient with novel CF corrector GLPG2222

20 January

Galapagos creates new warrant plan

20 December

SAPHIRA 1 topline shows competitive clinical results in G551D patients

15 December

The Lancet publishes FITZROY study results with filgotinib in Crohn's disease

08 December

Start Phase 2b/3 study with filgotinib in ulcerative colitis

29 November

Galapagos increases share capital through warrant exercises

28 November

Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737

24 November

Galapagos selected for Stoxx Europe 600 Index

22 November

Phase 3 study with filgotinib initiated in Crohn's disease

27 October

Robust progress in Q3 2016

27 October

Galapagos to present progress in CF programs at NACFC 2016

12 October

Transparency notification - FMR LLC reaches 10% threshold

11 October

Invitation to Galapagos investor relations program @ NACFC 2016

29 September

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

27 September

Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease

26 September

Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

19 September

Galapagos increases share capital through warrant exercises

06 September

Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis

22 August

FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis

29 July

Galapagos receives transparency notification from Federated

28 July

Focus on filgotinib and cystic fibrosis

23 June

Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors

15 June

Galapagos' R&D Update 2016

09 June

Galapagos selected for AEX Index

01 June

Galapagos creates new warrant plan

25 May

FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016

24 May

Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)

19 May

Galapagos increases share capital through warrant exercises

17 May

Listing of existing shares on Euronext Brussels & Amsterdam

09 May

Galapagos starts Phase 1 study with potentiator GLPG2451 for CF

29 April

Galapagos and AbbVie expand their cystic fibrosis collaboration

28 April

Galapagos kick-starts 2016 with Q1 cash position of €988 M

21 April

Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study

07 April

Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106

06 April

Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients

01 April

Galapagos increases share capital through warrant exercises

25 March

Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings

18 March

Results from 10-week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO

16 March

Galapagos doses first CF patient with G551D mutation in SAPHIRA 1 study

07 March

Galapagos selected for BEL 20 Index

03 March

Galapagos reports largest cash balance ever

01 March

Galapagos receives transparency notification from Johnson & Johnson

16 February

Galapagos starts SAPHIRA Phase 2 study with GLPG1837 in cystic fibrosis patients

01 February

Galapagos receives transparency notification from Wellington Management Group LLP

26 January

Galapagos reports results with GLPG1205 in ulcerative colitis

25 January

Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares

19 January

Galapagos and Gilead complete closing of their global collaboration for filgotinib

19 January

Galapagos advances CF clinical development

13 January

Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib

15 December

The Lancet publishes FITZROY study results with filgotinib in Crohn's disease

24 November

Galapagos selected for Stoxx Europe 600 Index

27 October

Galapagos to present progress in CF programs at NACFC 2016

11 October

Invitation to Galapagos investor relations program @ NACFC 2016

29 September

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

06 September

Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis

22 August

FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis

09 June

Galapagos selected for AEX Index

25 May

FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016

18 March

Results from 10-week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO

07 March

Galapagos selected for BEL 20 Index

20 December

SAPHIRA 1 topline shows competitive clinical results in G551D patients

08 December

Start Phase 2b/3 study with filgotinib in ulcerative colitis

29 November

Galapagos increases share capital through warrant exercises

28 November

Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737

22 November

Phase 3 study with filgotinib initiated in Crohn's disease

27 October

Robust progress in Q3 2016

12 October

Transparency notification - FMR LLC reaches 10% threshold

27 September

Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease

26 September

Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

19 September

Galapagos increases share capital through warrant exercises

29 July

Galapagos receives transparency notification from Federated

28 July

Focus on filgotinib and cystic fibrosis

23 June

Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors

15 June

Galapagos' R&D Update 2016

01 June

Galapagos creates new warrant plan

24 May

Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)

19 May

Galapagos increases share capital through warrant exercises

17 May

Listing of existing shares on Euronext Brussels & Amsterdam

09 May

Galapagos starts Phase 1 study with potentiator GLPG2451 for CF

29 April

Galapagos and AbbVie expand their cystic fibrosis collaboration

28 April

Galapagos kick-starts 2016 with Q1 cash position of €988 M

21 April

Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study

07 April

Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106

06 April

Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients

01 April

Galapagos increases share capital through warrant exercises

25 March

Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings

16 March

Galapagos doses first CF patient with G551D mutation in SAPHIRA 1 study

03 March

Galapagos reports largest cash balance ever

01 March

Galapagos receives transparency notification from Johnson & Johnson

16 February

Galapagos starts SAPHIRA Phase 2 study with GLPG1837 in cystic fibrosis patients

01 February

Galapagos receives transparency notification from Wellington Management Group LLP

26 January

Galapagos reports results with GLPG1205 in ulcerative colitis

25 January

Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares

19 January

Galapagos and Gilead complete closing of their global collaboration for filgotinib

19 January

Galapagos advances CF clinical development

13 January

Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib

22 December

Galapagos creates new warrant plans

22 December

Galapagos receives transparency notification from Wellington Management Group LLP

17 December

GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES

07 December

Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's disease

04 December

Galapagos increases share capital through warrant exercises

20 November

Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015

20 November

Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier

12 November

Galapagos reports third quarter 2015 cash position of €374 M

08 November

Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015

04 November

Dr. Christine Mummery appointed to Galapagos' Board of Directors

15 October

Galapagos advances triple combination therapy in cystic fibrosis

09 October

Positive safety and tolerability for novel potentiator GLPG1837

08 October

Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015

02 October

Galapagos raises €1.2 million through warrant exercises

25 September

Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis

22 September

Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS

10 August

DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib

06 August

Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib

05 August

Galapagos on track to deliver on pipeline in second half 2015

29 July

Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study

15 July

Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research

19 June

Galapagos raises €4.4 million through warrant exercises

18 June

Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients

15 June

AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference

10 June

Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment

26 May

Galapagos receives transparency notifications

19 May

Galapagos announces capital increase

19 May

Galapagos announces closing of NASDAQ IPO

18 May

Galapagos announces full exercise of underwriters' option to purchase additional shares

14 May

Galapagos raises $275 million gross proceeds with NASDAQ IPO

12 May

Galapagos announces size of global offering increased to $250 million

07 May

Johnson & Johnson Innovation - JJDC, Inc. indicate interest in $25 million worth of shares in Galapagos' global offering

06 May

Galapagos announces launch of proposed global offering

06 May

Galapagos listed 10 years on Euronext Amsterdam and Brussels

01 May

BNP Paribas notify of 4.8% shareholding in Galapagos

01 May

Galapagos creates new warrant plan

27 April

Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial

15 April

Galapagos files registration statement in the United States for a proposed global offering

14 April

Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B study

27 March

Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015

27 March

Galapagos raises €5.8 million through warrant exercises, Board and Executive Committee members invest

17 March

Galapagos regains rights to GLPG1690, announces end of alliance with Janssen

06 March

Galapagos to be included in Amsterdam Midcap Index

06 March

Galapagos reports 2014 financial results

23 February

Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment

16 February

Galapagos reports positive Phase 1 results for GLPG1690

11 February

Galapagos receives €1.6 million IWT grant for hepatitis B program

09 February

BNP Paribas notify of 5.08% shareholding in Galapagos

22 January

Galapagos receives €2.5 million IWT grant for antibiotic research

21 January

Delta Lloyd notify of 4.96% shareholding in Galapagos

09 January

Vicki Sato resigns from Galapagos Board

08 January

Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients

08 November

Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015

04 November

Dr. Christine Mummery appointed to Galapagos' Board of Directors

22 September

Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS

15 July

Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research

06 May

Galapagos listed 10 years on Euronext Amsterdam and Brussels

06 March

Galapagos to be included in Amsterdam Midcap Index

23 February

Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment

11 February

Galapagos receives €1.6 million IWT grant for hepatitis B program

22 January

Galapagos receives €2.5 million IWT grant for antibiotic research

09 January

Vicki Sato resigns from Galapagos Board

08 January

Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients

22 December

Galapagos creates new warrant plans

22 December

Galapagos receives transparency notification from Wellington Management Group LLP

17 December

GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES

07 December

Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's disease

04 December

Galapagos increases share capital through warrant exercises

20 November

Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015

20 November

Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier

12 November

Galapagos reports third quarter 2015 cash position of €374 M

15 October

Galapagos advances triple combination therapy in cystic fibrosis

09 October

Positive safety and tolerability for novel potentiator GLPG1837

08 October

Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015

02 October

Galapagos raises €1.2 million through warrant exercises

25 September

Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis

10 August

DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib

06 August

Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib

05 August

Galapagos on track to deliver on pipeline in second half 2015

29 July

Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study

19 June

Galapagos raises €4.4 million through warrant exercises

18 June

Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients

15 June

AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference

10 June

Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment

26 May

Galapagos receives transparency notifications

19 May

Galapagos announces capital increase

19 May

Galapagos announces closing of NASDAQ IPO

18 May

Galapagos announces full exercise of underwriters' option to purchase additional shares

14 May

Galapagos raises $275 million gross proceeds with NASDAQ IPO

12 May

Galapagos announces size of global offering increased to $250 million

07 May

Johnson & Johnson Innovation - JJDC, Inc. indicate interest in $25 million worth of shares in Galapagos' global offering

06 May

Galapagos announces launch of proposed global offering

01 May

BNP Paribas notify of 4.8% shareholding in Galapagos

01 May

Galapagos creates new warrant plan

27 April

Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial

15 April

Galapagos files registration statement in the United States for a proposed global offering

14 April

Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B study

27 March

Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015

27 March

Galapagos raises €5.8 million through warrant exercises, Board and Executive Committee members invest

17 March

Galapagos regains rights to GLPG1690, announces end of alliance with Janssen

06 March

Galapagos reports 2014 financial results

16 February

Galapagos reports positive Phase 1 results for GLPG1690

09 February

BNP Paribas notify of 5.08% shareholding in Galapagos

21 January

Delta Lloyd notify of 4.96% shareholding in Galapagos

19 December

Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie

16 December

Galapagos regains full rights to GPR84 inhibitor GLPG1205

12 December

Galapagos selects second component of its investigational cystic fibrosis combination treatment

09 December

Galapagos increases share capital through warrant exercises

24 November

Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA

17 November

Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014

12 November

Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA

06 November

GSK discloses good efficacy in psoriasis with GSK2856184

27 October

Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK

20 October

Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week

17 October

Galapagos creates new warrant plan

15 October

Bart Filius joins Galapagos as CFO

09 October

Galapagos presents novel cystic fibrosis combination therapy at NACFC

25 September

Galapagos increases share capital through warrant exercises

18 September

Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients

08 August

Galapagos cash position of €232 M provides solid basis for R&D pipeline investment

05 August

Galapagos receives milestone in osteoarthritis alliance with Servier

25 July

Galapagos creates new warrant plan

23 July

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

04 July

Galapagos raises €1.9 million through warrant exercises

01 July

Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV

17 June

Galapagos cystic fibrosis program progresses towards therapy for largest patient group

12 May

Galapagos to hold Annual R&D Update on 17 June 2014 in New York

30 April

Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014

28 April

Galapagos announces management change

24 April

Baker Brothers notify of 4.99% shareholding in Galapagos

17 April

GSK2586184 met primary endpoint in Phase 2a psoriasis study

10 April

Galapagos raises €2.4 million through warrant exercises

01 April

Charles River Laboratories and Galapagos complete transaction

28 March

Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April 2014

21 March

Euronext Amsterdam to become Market of Reference for Galapagos

18 March

Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego

13 March

Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 million

07 March

Galapagos reports 2013 financial results

07 March

Galapagos receives €2 million from osteoarthritis alliance with Servier

28 February

Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis clinical studies

21 February

Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD

17 February

Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis

03 February

Galapagos receives €2.3 million IWT grant for fibrosis research

29 January

First clinical centers opened for Phase 2 Crohn's study with GLPG0634

13 January

Galapagos receives €2.9 million IWT grant for cystic fibrosis research

06 January

Van Herk Investments notify of 5.3% shareholding in Galapagos

19 December

Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie

16 December

Galapagos regains full rights to GPR84 inhibitor GLPG1205

12 December

Galapagos selects second component of its investigational cystic fibrosis combination treatment

09 December

Galapagos increases share capital through warrant exercises

24 November

Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA

17 November

Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014

12 November

Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA

06 November

GSK discloses good efficacy in psoriasis with GSK2856184

27 October

Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK

20 October

Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week

17 October

Galapagos creates new warrant plan

15 October

Bart Filius joins Galapagos as CFO

09 October

Galapagos presents novel cystic fibrosis combination therapy at NACFC

25 September

Galapagos increases share capital through warrant exercises

18 September

Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients

08 August

Galapagos cash position of €232 M provides solid basis for R&D pipeline investment

05 August

Galapagos receives milestone in osteoarthritis alliance with Servier

25 July

Galapagos creates new warrant plan

23 July

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

04 July

Galapagos raises €1.9 million through warrant exercises

01 July

Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV

17 June

Galapagos cystic fibrosis program progresses towards therapy for largest patient group

12 May

Galapagos to hold Annual R&D Update on 17 June 2014 in New York

30 April

Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014

28 April

Galapagos announces management change

24 April

Baker Brothers notify of 4.99% shareholding in Galapagos

17 April

GSK2586184 met primary endpoint in Phase 2a psoriasis study

10 April

Galapagos raises €2.4 million through warrant exercises

01 April

Charles River Laboratories and Galapagos complete transaction

28 March

Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April 2014

21 March

Euronext Amsterdam to become Market of Reference for Galapagos

18 March

Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego

13 March

Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 million

07 March

Galapagos reports 2013 financial results

07 March

Galapagos receives €2 million from osteoarthritis alliance with Servier

28 February

Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis clinical studies

21 February

Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD

17 February

Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis

03 February

Galapagos receives €2.3 million IWT grant for fibrosis research

29 January

First clinical centers opened for Phase 2 Crohn's study with GLPG0634

13 January

Galapagos receives €2.9 million IWT grant for cystic fibrosis research

06 January

Van Herk Investments notify of 5.3% shareholding in Galapagos

16 December

Galapagos selects pre-clinical candidate for cystic fibrosis

06 December

Galapagos increases share capital through warrant exercises

04 December

Galapagos reports positive Phase 1 results for GLPG1205

27 November

Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis

20 November

Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim

15 November

Galapagos business update

12 November

Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma

21 October

Galapagos increases share capital through warrant exercises

17 October

Galapagos presents superior potentiator series for CF

16 October

Galapagos to present GLPG0634 at ACR

16 October

Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin

30 September

Delta Lloyd notify of 9.93% shareholding in Galapagos

24 September

AbbVie and Galapagos to co-develop cystic fibrosis therapies

18 September

Galapagos creates new warrant plan

20 August

Galapagos appoints David Smith as CEO of Service Division

09 August

Galapagos half year revenues up 21%

23 July

Galapagos delivers novel osteoarthritis molecules in alliance with Servier

08 July

Galapagos receives €2.4 million IWT grant for psoriasis research

02 July

Galapagos initiates Phase 1 trial as part of its alliance with Janssen Pharmaceutica NV

01 July

Galapagos increases share capital through warrant exercises

01 July

First patients screened for Phase 2B studies with GLPG0634

13 June

Galapagos presents GLPG0634 at EULAR poster session

17 May

Galapagos creates new warrant plan

17 May

Galapagos business update

17 May

AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease

13 May

Galapagos to present three posters on GLPG0634 at EULAR

30 April

NYSE Liffe lists Equity Options on Galapagos

29 April

Galapagos completes private placement by issuance of 2,696,831 new ordinary shares

25 April

Galapagos raises €54 million

24 April

Galapagos to raise capital via a private placement of new shares

23 April

Galapagos starts Phase 2A study with GLPG0974 in ulcerative colitis

22 April

Galapagos discovers novel candidate drug to treat breast cancer

16 April

Galapagos presents scope of GLPG0634 Phase 2b program

12 April

Gestion notify of 4.97% shareholding in Galapagos

08 April

Galapagos increases share capital through warrant exercises

27 March

Galapagos to start Phase 2a study with GLPG0974 in IBD patients

27 March

Galapagos gives R&D Update

20 March

Galapagos to host annual R&D update on 27 March

08 March

Galapagos reports record revenues in 2012, increasing momentum in clinical pipeline

08 March

Galapagos and Roche conclude strategic alliance

06 March

Galapagos receives €7.5 million in Servier alliances

04 March

Katrine Bosley appointed to Galapagos' Board of Directors

05 February

Galapagos announces GSK2586184 JAK1 molecule progresses to Phase 2 studies

30 January

Galapagos receives €2.5 million IWT grant for IBD research

16 January

Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica NV and receives €4 million milestone payment

15 January

Galapagos creates Fidelta, a third Galapagos service division

15 January

Galapagos acquires Cangenix, a structure-based drug discovery company

10 January

Galapagos receives €2.7 million IWT grant for antibacterial research

09 January

Galapagos delivers candidate drug in GSK alliance and receives milestone payment

06 January

Galapagos to present at the 31st annual J. P. Morgan Healthcare Conference

06 January

Galapagos to present at the 31st annual J. P. Morgan Healthcare Conference

16 December

Galapagos selects pre-clinical candidate for cystic fibrosis

06 December

Galapagos increases share capital through warrant exercises

04 December

Galapagos reports positive Phase 1 results for GLPG1205

27 November

Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis

20 November

Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim

15 November

Galapagos business update

12 November

Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma

21 October

Galapagos increases share capital through warrant exercises

17 October

Galapagos presents superior potentiator series for CF

16 October

Galapagos to present GLPG0634 at ACR

16 October

Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin

30 September

Delta Lloyd notify of 9.93% shareholding in Galapagos

24 September

AbbVie and Galapagos to co-develop cystic fibrosis therapies

18 September

Galapagos creates new warrant plan

20 August

Galapagos appoints David Smith as CEO of Service Division

09 August

Galapagos half year revenues up 21%

23 July

Galapagos delivers novel osteoarthritis molecules in alliance with Servier

08 July

Galapagos receives €2.4 million IWT grant for psoriasis research

02 July

Galapagos initiates Phase 1 trial as part of its alliance with Janssen Pharmaceutica NV

01 July

Galapagos increases share capital through warrant exercises

01 July

First patients screened for Phase 2B studies with GLPG0634

13 June

Galapagos presents GLPG0634 at EULAR poster session

17 May

Galapagos creates new warrant plan

17 May

Galapagos business update

17 May

AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease

13 May

Galapagos to present three posters on GLPG0634 at EULAR

30 April

NYSE Liffe lists Equity Options on Galapagos

29 April

Galapagos completes private placement by issuance of 2,696,831 new ordinary shares

25 April

Galapagos raises €54 million

24 April

Galapagos to raise capital via a private placement of new shares

23 April

Galapagos starts Phase 2A study with GLPG0974 in ulcerative colitis

22 April

Galapagos discovers novel candidate drug to treat breast cancer

16 April

Galapagos presents scope of GLPG0634 Phase 2b program

12 April

Gestion notify of 4.97% shareholding in Galapagos

08 April

Galapagos increases share capital through warrant exercises

27 March

Galapagos to start Phase 2a study with GLPG0974 in IBD patients

27 March

Galapagos gives R&D Update

20 March

Galapagos to host annual R&D update on 27 March

08 March

Galapagos reports record revenues in 2012, increasing momentum in clinical pipeline

08 March

Galapagos and Roche conclude strategic alliance

06 March

Galapagos receives €7.5 million in Servier alliances

04 March

Katrine Bosley appointed to Galapagos' Board of Directors

05 February

Galapagos announces GSK2586184 JAK1 molecule progresses to Phase 2 studies

30 January

Galapagos receives €2.5 million IWT grant for IBD research

16 January

Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica NV and receives €4 million milestone payment

15 January

Galapagos creates Fidelta, a third Galapagos service division

15 January

Galapagos acquires Cangenix, a structure-based drug discovery company

10 January

Galapagos receives €2.7 million IWT grant for antibacterial research

09 January

Galapagos delivers candidate drug in GSK alliance and receives milestone payment

17 December

Galapagos increases share capital through warrant exercises

03 December

Galapagos opens IND for GLPG0634 in the US

26 November

Galapagos discovers novel class of antibiotics

16 November

Galapagos business update

12 November

Galapagos receives positive ruling on Patent Income Deduction

11 November

GLPG0634 single center Proof of Concept results to be presented at American College of Rheumatology Annual meeting

08 November

GLPG0634 Phase 2A multicenter trial shows dose-response, confirms excellent safety and significant clinical benefit in rheumatoid arthritis patients

24 October

Galapagos initiates second Phase I study with GLPG0974

14 September

Galapagos increases share capital through warrant exercises

07 September

The Capital Group Companies notify of 5.85% shareholding in Galapagos

04 September

Johnson & Johnson notify of 8.8% shareholding in Galapagos

03 September

Galapagos creates new warrant plans

03 September

Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders

03 August

Galapagos delivers solid half year results 2012

24 July

Galapagos delivers candidate drug in osteoarthritis alliance with Servier

18 July

Baker Brothers notify of 6.5% shareholding in Galapagos

29 June

Galapagos increases share capital through warrant exercises

22 June

Galapagos wins 2012 European Mediscience Awards

05 June

Galapagos to present GLPG0634 Phase II POC results at EULAR

30 May

Ono and Galapagos subsidiary BioFocus sign an additional target discovery agreement in the field of allergic disease

23 May

Galapagos receives transparency notification

18 May

Galapagos NV: business update

14 May

Galapagos initiates Phase IIa study with GLPG0634

27 April

Galapagos EGM convocation

18 April

Galapagos gives R&D update

05 April

Galapagos increases share capital through warrant exercises

23 March

Galapagos NV: Convocation Annual General Shareholder Meeting

21 March

Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica, NV and receives milestone payment

06 March

Galapagos receives transparency notification

02 March

Galapagos NV : Pipeline promise confirmed: mixed financial results for 2011, but with excellent outlook for 2012

02 March

Galapagos receives €3.5 million in milestones in osteoarthritis alliance with Servier

29 February

Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases

21 February

Galapagos announces GSK decision to exercise option for investigational medicines GLPG0778 and GLPG0555

25 January

Almirall and Galapagos enter research alliance

11 November

GLPG0634 single center Proof of Concept results to be presented at American College of Rheumatology Annual meeting

30 May

Ono and Galapagos subsidiary BioFocus sign an additional target discovery agreement in the field of allergic disease

17 December

Galapagos increases share capital through warrant exercises

03 December

Galapagos opens IND for GLPG0634 in the US

26 November

Galapagos discovers novel class of antibiotics

16 November

Galapagos business update

12 November

Galapagos receives positive ruling on Patent Income Deduction

08 November

GLPG0634 Phase 2A multicenter trial shows dose-response, confirms excellent safety and significant clinical benefit in rheumatoid arthritis patients

24 October

Galapagos initiates second Phase I study with GLPG0974

14 September

Galapagos increases share capital through warrant exercises

07 September

The Capital Group Companies notify of 5.85% shareholding in Galapagos

04 September

Johnson & Johnson notify of 8.8% shareholding in Galapagos

03 September

Galapagos creates new warrant plans

03 September

Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders

03 August

Galapagos delivers solid half year results 2012

24 July

Galapagos delivers candidate drug in osteoarthritis alliance with Servier

18 July

Baker Brothers notify of 6.5% shareholding in Galapagos

29 June

Galapagos increases share capital through warrant exercises

22 June

Galapagos wins 2012 European Mediscience Awards

05 June

Galapagos to present GLPG0634 Phase II POC results at EULAR

23 May

Galapagos receives transparency notification

18 May

Galapagos NV: business update

14 May

Galapagos initiates Phase IIa study with GLPG0634

27 April

Galapagos EGM convocation

18 April

Galapagos gives R&D update

05 April

Galapagos increases share capital through warrant exercises

23 March

Galapagos NV: Convocation Annual General Shareholder Meeting

21 March

Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica, NV and receives milestone payment

06 March

Galapagos receives transparency notification

02 March

Galapagos NV : Pipeline promise confirmed: mixed financial results for 2011, but with excellent outlook for 2012

02 March

Galapagos receives €3.5 million in milestones in osteoarthritis alliance with Servier

29 February

Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases

21 February

Galapagos announces GSK decision to exercise option for investigational medicines GLPG0778 and GLPG0555

25 January

Almirall and Galapagos enter research alliance

21 December

Galapagos initiates clinical study with GLPG0974, the first anti-inflammatory candidate drug targeting GPR43

19 December

Galapagos increases share capital through warrant exercises

19 December

Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance

15 December

Galapagos receives €4 million in milestones from Servier in their osteoarthritis alliance

22 November

Galapagos' GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study

10 November

Galapagos business update

07 November

Galapagos to present results for selective JAK1 inhibitor in rheumatoid arthritis patients on 22 November 2011

04 November

Galapagos wins 2011 Scrip Award for Biotech Company of the Year

12 October

Galapagos announces second extension to services collaboration with Chiesi

03 October

Servier and Galapagos initiate strategic alliance for innovative treatments in oncology

18 August

Galapagos and Genentech extend drug discovery collaboration

05 August

Galapagos announces half year results 2011

20 July

Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492

01 July

Galapagos increases share capital through warrant exercises

28 June

Argenta signs integrated services agreement with Pulmagen Therapeutics

09 June

Galapagos initiates Phase II trial for GLPG0634

01 June

Evotec acquires compound management business from Galapagos

30 May

Ronald Brus resigns from the Galapagos Board

24 May

Galapagos to deliver four presentations at EULAR 2011

23 May

Galapagos announces approval of all EGM proposals; creates new warrant plans

13 May

Galapagos business update

12 May

Galapagos receives transparency notifications

11 May

Galapagos initiates second Proof of Mechanism clinical study in GSK alliance

20 April

Galapagos delivers validated oncology targets to Janssen

15 April

Galapagos discontinues Phase II trial for GLPG0259, focuses resources on other rheumatoid arthritis programs

01 April

Dr Vicki Sato to be appointed to Galapagos' Board of Directors

30 March

Galapagos increases share capital through warrant exercises

14 March

Galapagos starts Phase Ib clinical study in cancer patients

04 March

Galapagos reports record revenues and increased profitability in 2010

02 March

Galapagos delivers candidate drug in GSK alliance, receives €6.7 million

08 February

Galapagos receives €4 million in milestones from Servier

07 February

Galapagos creates new warrant plan

07 February

Galapagos receives €2.7 million grant for antiviral drug discovery

04 February

Galapagos achieves €137 million revenues in 2010, outlook for continued strong 2011 performance

04 February

Galapagos and Merck & Co., Inc. agree to end strategic alliances

11 January

Galapagos receives €7.4 M milestone in arthritis alliance with GlaxoSmithKline

07 November

Galapagos to present results for selective JAK1 inhibitor in rheumatoid arthritis patients on 22 November 2011

04 November

Galapagos wins 2011 Scrip Award for Biotech Company of the Year

12 October

Galapagos announces second extension to services collaboration with Chiesi

24 May

Galapagos to deliver four presentations at EULAR 2011

21 December

Galapagos initiates clinical study with GLPG0974, the first anti-inflammatory candidate drug targeting GPR43

19 December

Galapagos increases share capital through warrant exercises

19 December

Galapagos achieves clinical Proof-of-Mechanism milestone in GSK alliance

15 December

Galapagos receives €4 million in milestones from Servier in their osteoarthritis alliance

22 November

Galapagos' GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study

10 November

Galapagos business update

03 October

Servier and Galapagos initiate strategic alliance for innovative treatments in oncology

18 August

Galapagos and Genentech extend drug discovery collaboration

05 August

Galapagos announces half year results 2011

20 July

Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492

01 July

Galapagos increases share capital through warrant exercises

28 June

Argenta signs integrated services agreement with Pulmagen Therapeutics

09 June

Galapagos initiates Phase II trial for GLPG0634

01 June

Evotec acquires compound management business from Galapagos

30 May

Ronald Brus resigns from the Galapagos Board

23 May

Galapagos announces approval of all EGM proposals; creates new warrant plans

13 May

Galapagos business update

12 May

Galapagos receives transparency notifications

11 May

Galapagos initiates second Proof of Mechanism clinical study in GSK alliance

20 April

Galapagos delivers validated oncology targets to Janssen

15 April

Galapagos discontinues Phase II trial for GLPG0259, focuses resources on other rheumatoid arthritis programs

01 April

Dr Vicki Sato to be appointed to Galapagos' Board of Directors

30 March

Galapagos increases share capital through warrant exercises

14 March

Galapagos starts Phase Ib clinical study in cancer patients

04 March

Galapagos reports record revenues and increased profitability in 2010

02 March

Galapagos delivers candidate drug in GSK alliance, receives €6.7 million

08 February

Galapagos receives €4 million in milestones from Servier

07 February

Galapagos creates new warrant plan

07 February

Galapagos receives €2.7 million grant for antiviral drug discovery

04 February

Galapagos achieves €137 million revenues in 2010, outlook for continued strong 2011 performance

04 February

Galapagos and Merck & Co., Inc. agree to end strategic alliances

11 January

Galapagos receives €7.4 M milestone in arthritis alliance with GlaxoSmithKline

17 December

Galapagos' affiliate BioFocus extends collaboration with Amgen into 2012

16 December

Galapagos achieves milestones, broadens scope of Roche alliance

07 December

Galapagos increases share capital through warrant exercises

02 December

Galapagos candidate cachexia drug, GLPG0492, shows good safety and profile suitable for once-daily oral dosing

12 November

Galapagos business update

01 November

Galapagos receives transparency notification

28 October

Galapagos receives €3.7 million grant for cystic fibrosis program

27 October

Galapagos receives transparency notifications

22 October

Galapagos completes private placement by issuance of 2,389,347 new ordinary shares

19 October

Galapagos successfully completes placement of 2,389,347 new ordinary shares

18 October

Galapagos announces offering of new ordinary shares

18 October

Galapagos achieves milestones in two strategic alliances

14 October

Galapagos' affiliate BioFocus extends collaboration with Chiesi

12 October

Galapagos and the National Cancer Institute sign compound management agreement

05 October

Galapagos wins 2010 European Biotechnica Award

04 October

Galapagos' affiliate Argenta and Janssen Pharmaceutica enter in integrated cancer drug discovery service agreement

28 September

Galapagos starts Phase II clinical trial in rheumatoid arthritis patients

10 September

Argenta expands collaboration with Genentech to include BioFocus

08 September

Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia

07 September

Galapagos announces appointment of Howard Rowe to Board of Directors, increases share capital through warrant exercises

06 August

Galapagos half year results in line with full year guidance

06 August

Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK

16 July

Galapagos and University of Bristol enter drug discovery collaboration in chronic pain

12 July

NIH extends agreement with Galapagos until end 2012

01 July

Servier and Galapagos initiate strategic alliance in osteoarthritis

29 June

Correction: transparency notification

28 June

Galapagos increases share capital through warrant exercises, receives transparency notifications

17 June

Apax shareholding in Galapagos placed with institutional investors

25 May

Galapagos achieves milestones in osteoporosis alliance

20 May

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia

14 May

Galapagos business update

11 May

Galapagos and Roche expand COPD alliance

29 April

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

28 April

Galapagos announces appointment of Ronald Brus to Board; creates new warrant plans

19 April

Galapagos to present GLPG0187 first-in-human trial results (cancelled)

08 April

Galapagos raises €2.1 million from warrant exercises, management increases shareholding

19 March

Galapagos to build cystic fibrosis drug pipeline

05 March

Galapagos reports record revenues and net profit for 2009, foresees sustained profitability

23 February

Galapagos successfully completes Phase I clinical trials for rheumatoid arthritis candidate drug GLPG0259

22 February

Galapagos delivers third candidate drug in GSK alliance, receives €5.7 million

19 February

Transparency information

18 February

Galapagos and MorphoSys expand antibody alliance

02 February

Galapagos acquires Argenta Discovery's service operations

29 January

Galapagos delivers strong 2009 performance, expects positive operating income in 2010

19 January

Galapagos candidate metastasis drug shows good safety and biomarker response

15 January

Galapagos achieves milestones in strategic alliances with Merck & Co., Inc.

12 January

Galapagos service division achieves EUR 1.6 M in payments

11 January

Galapagos and Roche initiate strategic alliance in COPD

10 September

Argenta expands collaboration with Genentech to include BioFocus

19 April

Galapagos to present GLPG0187 first-in-human trial results (cancelled)

17 December

Galapagos' affiliate BioFocus extends collaboration with Amgen into 2012

16 December

Galapagos achieves milestones, broadens scope of Roche alliance

07 December

Galapagos increases share capital through warrant exercises

02 December

Galapagos candidate cachexia drug, GLPG0492, shows good safety and profile suitable for once-daily oral dosing

12 November

Galapagos business update

01 November

Galapagos receives transparency notification

28 October

Galapagos receives €3.7 million grant for cystic fibrosis program

27 October

Galapagos receives transparency notifications

22 October

Galapagos completes private placement by issuance of 2,389,347 new ordinary shares

19 October

Galapagos successfully completes placement of 2,389,347 new ordinary shares

18 October

Galapagos announces offering of new ordinary shares

18 October

Galapagos achieves milestones in two strategic alliances

14 October

Galapagos' affiliate BioFocus extends collaboration with Chiesi

12 October

Galapagos and the National Cancer Institute sign compound management agreement

05 October

Galapagos wins 2010 European Biotechnica Award

04 October

Galapagos' affiliate Argenta and Janssen Pharmaceutica enter in integrated cancer drug discovery service agreement

28 September

Galapagos starts Phase II clinical trial in rheumatoid arthritis patients

08 September

Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia

07 September

Galapagos announces appointment of Howard Rowe to Board of Directors, increases share capital through warrant exercises

06 August

Galapagos half year results in line with full year guidance

06 August

Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK

16 July

Galapagos and University of Bristol enter drug discovery collaboration in chronic pain

12 July

NIH extends agreement with Galapagos until end 2012

01 July

Servier and Galapagos initiate strategic alliance in osteoarthritis

29 June

Correction: transparency notification

28 June

Galapagos increases share capital through warrant exercises, receives transparency notifications

17 June

Apax shareholding in Galapagos placed with institutional investors

25 May

Galapagos achieves milestones in osteoporosis alliance

20 May

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia

14 May

Galapagos business update

11 May

Galapagos and Roche expand COPD alliance

29 April

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

28 April

Galapagos announces appointment of Ronald Brus to Board; creates new warrant plans

08 April

Galapagos raises €2.1 million from warrant exercises, management increases shareholding

19 March

Galapagos to build cystic fibrosis drug pipeline

05 March

Galapagos reports record revenues and net profit for 2009, foresees sustained profitability

23 February

Galapagos successfully completes Phase I clinical trials for rheumatoid arthritis candidate drug GLPG0259

22 February

Galapagos delivers third candidate drug in GSK alliance, receives €5.7 million

19 February

Transparency information

18 February

Galapagos and MorphoSys expand antibody alliance

02 February

Galapagos acquires Argenta Discovery's service operations

29 January

Galapagos delivers strong 2009 performance, expects positive operating income in 2010

19 January

Galapagos candidate metastasis drug shows good safety and biomarker response

15 January

Galapagos achieves milestones in strategic alliances with Merck & Co., Inc.

12 January

Galapagos service division achieves EUR 1.6 M in payments

11 January

Galapagos and Roche initiate strategic alliance in COPD